Andere Sprachen Hoth Therapeutics, Inc.

Aktien

A3DZJ0

US44148G2049

HOTH

Verzögert Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
1.21 ^USD	-1.55%		+4.31%	-15.97%

28.03.	Hoth Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
19.03.	Wall Street eröffnet vor zweitägiger Fed-Sitzung schwächer; Wohnungsbaubeginne übertreffen die Erwartungen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024	01.05.
Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds	27.03.
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment	27.03.
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19.03.
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ	19.03.
Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ	19.03.
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic	26.02.
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024	13.02.
Hoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial Amendments	18.01.
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients	18.01.
Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients	18.01.
Hoth Therapeutics Gets University of Miami Approval to Enroll Patients in Skin Toxicities Treatment Trial; Shares Rise	27.12.
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami	27.12.
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami	27.12.
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies	05.12.
Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies	05.12.
Hoth Therapeutics to Advance HT-KIT After Positive Feedback From FDA	14.11.
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT	14.11.
Hoth Therapeutics, Inc. Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT	14.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hoth Therapeutics, Inc.

Aktien

A3DZJ0

US44148G2049

HOTH

Andere Sprachen

Filter